Somatrogon: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and NICE (England), among others, recommended or restricted somatrogon, while AOTMIT (Poland) and CIPM (Spain) did not recommend it.
Every record falls within a 1.7-year window, 2022 to 8 Mar 2024 — a compressed review cycle.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 4 of 11 records date from 2023 or later.
3 distinct indication wordings are recorded for somatrogon by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess somatrogon, in 2022; AOTMIT (Poland) did not open a file until 8 Mar 2024 — a moderate spread of 1.7 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 7 of 11 dated records fall in 2022 alone.
11 of the 18 agencies in this archive hold a record for somatrogon.
The full ledger for somatrogon reads 5 recommended, 2 not recommended, 1 other and 1 no benefit, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 8 Mar 2024 | programu lekowego „Leczenie niskorosłych dzieci z somatotropinową niedoczynnością przysadki (ICD-10: E23) | not recommended | source |
| NYE METODER (Norway) | 27 Aug 2023 | Behandling av veksthormonmangel hos barn. | decision recorded | source |
| AIFA (Italy) | 28 Mar 2023 | NGENLA è indicato per il trattamento di bambini e adolescenti a partire dai 3 anni di età con disturbi della crescita da… | innovative status not granted · reimbursed class A | source |
| NICE (England) | 1 Feb 2023 | NICE TA863 | recommended | source |
| TLV (Sweden) | 21 Oct 2022 | Ngenla ingår i högkostnadsskyddet | general subsidy | source |
6 further decisions for somatrogon, across 6 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- somatropin — same ATC class H01A — Pituitary and hypothalamic hormones
- pegvisomant — same ATC class H01A — Pituitary and hypothalamic hormones
- somapacitan — same ATC class H01A — Pituitary and hypothalamic hormones
- mosunetuzumab — also decided by AOTMIT in 2024Q1
- enzalutamide — also decided by AOTMIT in 2024Q1
- tafamidis — also decided by AOTMIT in 2024Q1
Coverage: 11 decisions for somatrogon from 11 agencies, 2022 to 2024. Data to 7 Sep 2026. ATC class H01A — Pituitary and hypothalamic hormones. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.